Neoadjuvant chemotherapy less commonly used in breast cancer

Published Date: 02 Mar 2023

Most women will have breast cancer surgery first if the initial consultation is with a surgeon. This study has been published as a preprint and has not yet been peer-reviewed.

Read Full News

Latest News

NDAs Are Illegal in Healthcare, Says Ethicist

Ethicist Art Caplan discusses nondisclosure agreements in healthcare.

Whole-Body MRI Predicts Surgery Outcomes in Ovarian Cancer

Whole-body diffusion-weighted MRI accurately predicts complete resection and survival outcomes after neoadjuvant chemotherapy in patients with advanced ovarian cancer.

Some With Low-Grade Serous Ovarian Cancer May Not Need Chemo

A subgroup analysis hints that chemotherapy may be skipped after complete resection, but the finding needs further study.

MRI Sharpens Prostate Cancer Risk Stratification

A meta-analysis of nearly 25,000 patients undergoing radical prostatectomy supports adding presurgery MRI findings to standard prognostic models to inform subsequent treatment.

Minimally Invasive Ablation Can Treat Small Kidney Tumors

Less invasive ablation treatment in patients with small renal tumors has a comparable risk for tumor progression to surgical resection, with fewer complications and shorter hospital stays.

177Lu-PSMA-617 Delays Progression in Prostate Cancer

177Lu-PSMA-617 delays disease progression at a significantly higher rate than standard of care in patients with oligometastatic hormone-sensitive prostate cancer.

Todays Updates

CAR-T Induces Deep, Durable Remission in Smoldering Myeloma

In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?

‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.

Dasatinib Fails to Improve Outcomes in CBF-AML

A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

CD39 Blockade Shows Potential in Early-Stage Lung Cancer

A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.

Measurable Residual Disease Predicts Real-World AML Relapse

A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.

Todays Updates

CAR-T Induces Deep, Durable Remission in Smoldering Myeloma

In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?

‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.

Dasatinib Fails to Improve Outcomes in CBF-AML

A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

CD39 Blockade Shows Potential in Early-Stage Lung Cancer

A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.

Measurable Residual Disease Predicts Real-World AML Relapse

A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.

Latest News

Ethicist Art Caplan discusses nondisclosure agreements in healthcare.

Whole-body diffusion-weighted MRI accurately predicts complete resection and survival outcomes after neoadjuvant chemotherapy in patients with advanced ovarian cancer.

A subgroup analysis hints that chemotherapy may be skipped after complete resection, but the finding needs further study.

A meta-analysis of nearly 25,000 patients undergoing radical prostatectomy supports adding presurgery MRI findings to standard prognostic models to inform subsequent treatment.

Less invasive ablation treatment in patients with small renal tumors has a comparable risk for tumor progression to surgical resection, with fewer complications and shorter hospital stays.

177Lu-PSMA-617 delays disease progression at a significantly higher rate than standard of care in patients with oligometastatic hormone-sensitive prostate cancer.

News All Time

Catholics May receive Organ Transplants From Animals, Vatican Says

The Vatican said on Tuesday that Catholics can receive transplants ⁠of animal tissues to address medical conditions, as procedures involving genetically modified pig or cow...

Lifelike 3D-Printed ‘Training Brains’ React Like Real Organs

Researchers create a new polymer that mimics the mechanical, thermal, and electromagnetic properties of brain tissue, driving new surgical and experimental uses.

Nerve Wrap Seen Speeding Erectile Recovery Post-Prostatectomy

Dehydrated human amniotic membrane appears promising in observational findings from a large dataset.

Stryker Cyberattack Delays Surgeries for Some Patients, Bloomberg News Reports

A cyberattack against medical device maker Stryker last ⁠week has delayed surgeries for some patients, Bloomberg News ⁠reported on Wednesday.

New Strategies Drive Success in Crohn’s Disease Care

In the management of Crohn’s disease, a key objective — preserving the bowel by reducing the need for multiple resections — is gaining ground.

Analysis-Middle East War Disrupts Pharma Air Routes, Risks Cancer Drugs Supply

War in the Middle East is disrupting the flow of critical medicines to the Gulf, imperilling supply routes for cancer drugs and other treatments that require refrigeration...

Does ADT Improve Survival After PORT in Prostate Cancer?

A meta-analysis explores whether there’s a survival benefit to adding hormone therapy to postoperative radiation for patients with low PSA levels.

Exercise and Lifestyle Help Manage Ankylosing Spondylitis

Evidence shows supervised exercise programs significantly improve function and quality of life in patients with axial spondyloarthritis.

Can Local Therapy Extend Life in Metastatic Breast Cancer?

For some women with de novo metastatic breast cancer, surgical resection of the primary tumor is associated with longer survival.

How to Talk to Your Patients About Exercise and Pain

Some are afraid to move if it hurts. Some push too hard. Everyone agrees that exercise reduces chronic pain and enhances health — but how do you keep patients on track?

CEM Matches MRI for Nipple-Areola Analysis in Breast Cancer

Contrast-enhanced mammography offers a reliable alternative to MRI in evaluating nipple-areola complex involvement in patients with breast cancer before surgery.

PSA May Predict Hormone Therapy Benefit Post-Prostatectomy

A meta-analysis seeks to determine if adding hormone therapy to radiotherapy after prostatectomy improves overall survival.

Life in the Endless Scroll: What We're Losing

What looks like harmless screen time may be altering emotional resilience and cognitive focus in young users.

Doc Pay Boosted $400 Million With New Medicare Billing Code

A new JAMA study shows that a new Medicare billing code may have benefited specialists more than the primary care physicians it was designed to help most.

MRI-Guided Chemotherapy Improves Survival in Breast Cancer

MRI-guided personalisation of neoadjuvant chemotherapy duration is associated with improved 3-year survival outcomes in patients with stage II-III HER2-positive breast cancer, a new trial reports.

NICE Backs Paperclip-Sized Sensor for Heart Failure Care

The CardioMEMS HF System enables daily home monitoring and has been shown to reduce hospital admissions in high-risk patients with chronic heart failure.

Recommended News For You

Since 2000, the outlook for multiple myeloma has improved.

A novel blood test may enable the early identification of common, fatal cancers.

Durvalumab Wins FDA Approval in Limited-Stage SCLC

Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC

Ketamine plus psychotherapy for "excellent" PTSD

Hereditary cancer has a rare and underreported cause.

Dissociative identity disorder: method or fact?

Recommended Articles For You

The Evolving Arsenal: A 2025 Review of Antibody-Drug Conjugates and the Future of Precision Oncology 

The Latest Research on Wiskott Aldrich Syndrome  

Bridging Heart and Cancer Care: The Essential Framework of a Modern Cardio-Oncology Program 

Revolutionizing Lung Transplantation: The Promise of Donor-Specific Blood Transfusion 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Numerous Oncologists Are Concerned About the Cost of Genomic Testing.

2.

According to new studies, some cancer patients can safely forego radiation therapy.

3.

TRK Inhibitor Active in Treatment-Refractory Glioblastoma

4.

Guidelines for cervical cancer screening and the risk of preterm birth in young women.

5.

Pretreatment Liver Tests Often Overlooked in CDK4/6 Therapy

1.

Understanding Thrombin Time: What It Is and How It Can Help Diagnose Blood Clotting Disorders

2.

Biomimetic Nanovesicles for Breast Cancer: Targeting Senescence to Overcome Chemoresistance

3.

Chemotherapy Advances: Albumin I.V., Trastuzumab, Liposomal Doxorubicin & More

4.

Integrating Immunotherapy and Staging Guidelines in Lung Cancer Treatment

5.

Unveiling the Mystery Behind Lymphovascular Invasion

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment

2.

Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL

3.

Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC

4.

A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC

5.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot